The International Cancer Genome Consortium is entering a new phase in its research, as the organization is beginning to link genomics data to clinical information, with the hope of giving physicians far more precise and personalized treatment data.

The consortium began its work in 2008, when it started mapping thousands of different cancer genomes, representing 50 different types of cancer, in anticipation of a new era of precision medicine. About 15,000 cancers have been mapped by the International Cancer Genome Consortium (ICGC), with the goal of creating a catalog of mutations across the globe and making it available to researchers. ICGC expects to surpass 25,000 mappings by 2018.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access